Retrophin's Focus Shifts After Phase III PKAN Drug's Failure

 
• By Joseph Haas
  
Child-Sorrow
Retrophin misses its Phase III endpoint in PKAN, which typically manifests in childhood
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D